HLS Therapeutics (HLS) Hits New 1-Year High at $16.10

HLS Therapeutics Inc (CVE:HLS)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as C$16.10 and last traded at C$16.04, with a volume of 33149 shares traded. The stock had previously closed at C$15.75.

The company has a debt-to-equity ratio of 69.24, a quick ratio of 2.17 and a current ratio of 2.30.

HLS Therapeutics (CVE:HLS) last issued its earnings results on Wednesday, August 15th. The company reported C($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C($0.15) by C$0.12. The firm had revenue of C$21.04 million during the quarter, compared to the consensus estimate of C$20.77 million. As a group, equities analysts predict that HLS Therapeutics Inc will post -0.04 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.wkrb13.com/2018/11/08/hls-therapeutics-hls-hits-new-1-year-high-at-16-10.html.

HLS Therapeutics Company Profile (CVE:HLS)

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company was incorporated in 2014 and is headquartered in Toronto, Canada.

Further Reading: How can you know how many shares are floating?

Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply